Cargando…

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials

Programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) inhibitors are increasingly used in a variety of solid tumors. In patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer, their efficacy has been demonst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cancanelli, Luca, Rivano, Melania, Di Spazio, Lorenzo, Chiumente, Marco, Mengato, Daniele, Messori, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710086/ https://www.ncbi.nlm.nih.gov/pubmed/34966607 http://dx.doi.org/10.7759/cureus.19893

Ejemplares similares

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
por: Messori, Andrea, et al.
Publicado: (2023)

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
por: Messori, Andrea, et al.
Publicado: (2022)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis
por: Damuzzo, Vera, et al.
Publicado: (2021)

Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer
por: Sharma, Antariksha, et al.
Publicado: (2023)

Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability
por: Deshpande, Madhura, et al.
Publicado: (2020)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave
por: Damuzzo, Vera, et al.
Publicado: (2022)

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
por: Ossato, Andrea, et al.
Publicado: (2022)

Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer (Review)
por: Choucair, Khalil, et al.
Publicado: (2021)

Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs
por: Inanaga, Sakuya, et al.
Publicado: (2022)

Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method
por: Trippoli, Sabrina, et al.
Publicado: (2022)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?
por: Qiu, Yan-Yu, et al.
Publicado: (2023)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China
por: Zhang, Xiangyan, et al.
Publicado: (2018)

Hand hygiene for healthcare workers: did we need COVID-19 to raise awareness of proper disinfection practice?
por: Mengato, Daniele, et al.
Publicado: (2022)

Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
por: Gutierrez, Martin E., et al.
Publicado: (2019)

Non-classical phenotypes of mismatch repair deficiency and microsatellite instability in primary and metastatic tumors at different sites in Lynch syndrome
por: Li, Zhiyu, et al.
Publicado: (2022)

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital
por: Chiumente, Marco, et al.
Publicado: (2021)

Concordance between microsatellite instability testing and immunohistochemistry for mismatch repair proteins and efficient screening of mismatch repair deficient gastric cancer
por: Yamamoto, Gou, et al.
Publicado: (2023)

DNA Mismatch Repair Deficiency Detection in Colorectal Cancer by a New Microsatellite Instability Analysis System
por: Wu, Shafei, et al.
Publicado: (2020)

Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review
por: Mei, Wei-Jian, et al.
Publicado: (2022)

Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
por: Ossato, Andrea, et al.
Publicado: (2023)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers
por: Noh, Joseph J., et al.
Publicado: (2022)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
por: Liu, Ding-Xin, et al.
Publicado: (2020)

Evaluation of Concordance Between Deficient Mismatch Repair and Microsatellite Instability Testing and Their Association with Clinicopathological Features in Colorectal Cancer
por: Bai, Huili, et al.
Publicado: (2020)

WRN suppresses p53/PUMA-induced apoptosis in colorectal cancer with microsatellite instability/mismatch repair deficiency
por: Sobol, Robert W.
Publicado: (2023)

Saffron and Its Major Ingredients’ Effect on Colon Cancer Cells with Mismatch Repair Deficiency and Microsatellite Instability
por: Amin, Amr, et al.
Publicado: (2021)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies
por: Li, Ying-Jie, et al.
Publicado: (2023)

Microsatellite Instability Use in Mismatch Repair Gene Sequence Variant Classification
por: Thompson, Bryony A., et al.
Publicado: (2015)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
por: Le, Dung T., et al.
Publicado: (2020)

Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer
por: Eriksson, Jennifer, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lk13jv46qb1iumme8mftmq4ttb